Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pe… Read more
Ionis Pharmaceuticals Inc (IONS) - Net Assets
Latest net assets as of September 2025: $617.97 Million USD
Based on the latest financial reports, Ionis Pharmaceuticals Inc (IONS) has net assets worth $617.97 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.03 Billion) and total liabilities ($2.42 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $617.97 Million |
| % of Total Assets | 20.37% |
| Annual Growth Rate | 18.76% |
| 5-Year Change | -30.21% |
| 10-Year Change | 193.02% |
| Growth Volatility | 1620.95 |
Ionis Pharmaceuticals Inc - Net Assets Trend (1990–2024)
This chart illustrates how Ionis Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ionis Pharmaceuticals Inc (1990–2024)
The table below shows the annual net assets of Ionis Pharmaceuticals Inc from 1990 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $588.35 Million | +52.15% |
| 2023-12-31 | $386.69 Million | -32.50% |
| 2022-12-31 | $572.89 Million | -25.79% |
| 2021-12-31 | $772.00 Million | -8.42% |
| 2020-12-31 | $843.00 Million | -49.97% |
| 2019-12-31 | $1.69 Billion | +41.94% |
| 2018-12-31 | $1.19 Billion | +183.52% |
| 2017-12-31 | $418.72 Million | +320.55% |
| 2016-12-31 | $99.56 Million | -50.41% |
| 2015-12-31 | $200.79 Million | -22.11% |
| 2014-12-31 | $257.78 Million | -31.87% |
| 2013-12-31 | $378.39 Million | +107.04% |
| 2012-12-31 | $182.77 Million | +6.61% |
| 2011-12-31 | $171.43 Million | -29.90% |
| 2010-12-31 | $244.54 Million | -19.04% |
| 2009-12-31 | $302.06 Million | +189.76% |
| 2008-12-31 | $104.25 Million | +917.75% |
| 2007-12-31 | $10.24 Million | -89.54% |
| 2006-12-31 | $97.90 Million | +3573.62% |
| 2005-12-31 | $2.67 Million | +103.69% |
| 2004-12-31 | $-72.13 Million | -207.38% |
| 2003-12-31 | $67.18 Million | -56.79% |
| 2002-12-31 | $155.48 Million | -30.31% |
| 2001-12-31 | $223.10 Million | +236.16% |
| 2000-12-31 | $66.37 Million | +8195.75% |
| 1999-12-31 | $800.00K | +119.05% |
| 1998-12-31 | $-4.20 Million | -112.03% |
| 1997-12-31 | $34.90 Million | -40.24% |
| 1996-12-31 | $58.40 Million | -23.06% |
| 1995-12-31 | $75.90 Million | +65.00% |
| 1994-12-31 | $46.00 Million | -21.37% |
| 1993-12-31 | $58.50 Million | +46.98% |
| 1992-12-31 | $39.80 Million | -32.66% |
| 1991-12-31 | $59.10 Million | +3376.47% |
| 1990-12-31 | $1.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ionis Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 224260800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $158.00K | 0.03% |
| Other Comprehensive Income | $-30.81 Million | -5.24% |
| Other Components | $2.87 Billion | 487.60% |
| Total Equity | $588.35 Million | 100.00% |
Ionis Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Ionis Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Samsara Inc
NYSE:IOT
|
$11.61 Billion |
|
Sumitomo Electric Industries Ltd
PINK:SMTOF
|
$11.62 Billion |
|
Bajaj Auto Limited
NSE:BAJAJ-AUTO
|
$11.62 Billion |
|
Zhejiang Sanhua Co Ltd
SHE:002050
|
$11.62 Billion |
|
IONQ Inc
NYSE:IONQ
|
$11.58 Billion |
|
Tele2 AB (publ)
ST:TEL2-B
|
$11.57 Billion |
|
Bajaj Finserv Limited
NSE:BAJAJFINSV
|
$11.55 Billion |
|
Nova Measuring Instruments Ltd
F:NMR
|
$11.55 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ionis Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 386,686,000 to 588,351,000, a change of 201,665,000 (52.2%).
- Net loss of 453,897,000 reduced equity.
- New share issuances of 522,729,000 increased equity.
- Other comprehensive income increased equity by 1,834,000.
- Other factors increased equity by 130,999,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-453.90 Million | -77.15% |
| Share Issuances | $522.73 Million | +88.85% |
| Other Comprehensive Income | $1.83 Million | +0.31% |
| Other Changes | $131.00 Million | +22.27% |
| Total Change | $- | 52.15% |
Book Value vs Market Value Analysis
This analysis compares Ionis Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 18.38x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 273.52x to 18.38x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1990-12-31 | $0.26 | $72.33 | x |
| 1991-12-31 | $5.71 | $72.33 | x |
| 1992-12-31 | $3.08 | $72.33 | x |
| 1993-12-31 | $3.74 | $72.33 | x |
| 1994-12-31 | $2.35 | $72.33 | x |
| 1995-12-31 | $3.52 | $72.33 | x |
| 1996-12-31 | $2.29 | $72.33 | x |
| 1997-12-31 | $1.31 | $72.33 | x |
| 1998-12-31 | $-0.16 | $72.33 | x |
| 1999-12-31 | $0.03 | $72.33 | x |
| 2000-12-31 | $1.79 | $72.33 | x |
| 2001-12-31 | $5.06 | $72.33 | x |
| 2002-12-31 | $2.85 | $72.33 | x |
| 2003-12-31 | $1.21 | $72.33 | x |
| 2004-12-31 | $-1.27 | $72.33 | x |
| 2005-12-31 | $0.04 | $72.33 | x |
| 2006-12-31 | $0.92 | $72.33 | x |
| 2007-12-31 | $0.01 | $72.33 | x |
| 2008-12-31 | $0.71 | $72.33 | x |
| 2009-12-31 | $2.97 | $72.33 | x |
| 2010-12-31 | $2.47 | $72.33 | x |
| 2011-12-31 | $1.72 | $72.33 | x |
| 2012-12-31 | $1.82 | $72.33 | x |
| 2013-12-31 | $3.42 | $72.33 | x |
| 2014-12-31 | $2.19 | $72.33 | x |
| 2015-12-31 | $1.68 | $72.33 | x |
| 2016-12-31 | $0.82 | $72.33 | x |
| 2017-12-31 | $2.62 | $72.33 | x |
| 2018-12-31 | $7.82 | $72.33 | x |
| 2019-12-31 | $10.30 | $72.33 | x |
| 2020-12-31 | $6.04 | $72.33 | x |
| 2021-12-31 | $5.47 | $72.33 | x |
| 2022-12-31 | $4.04 | $72.33 | x |
| 2023-12-31 | $2.70 | $72.33 | x |
| 2024-12-31 | $3.94 | $72.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ionis Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -77.15%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -64.37%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 5.11x
- Recent ROE (-77.15%) is above the historical average (-365.51%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1990 | -264.71% | -225.00% | 0.47x | 2.53x | $-4.67 Million |
| 1991 | -14.72% | -138.10% | 0.09x | 1.25x | $-14.61 Million |
| 1992 | -48.99% | -224.14% | 0.16x | 1.39x | $-23.48 Million |
| 1993 | -32.65% | -157.85% | 0.15x | 1.35x | $-24.95 Million |
| 1994 | -39.57% | -180.20% | 0.15x | 1.45x | $-22.80 Million |
| 1995 | -31.23% | -182.31% | 0.13x | 1.31x | $-31.29 Million |
| 1996 | -45.38% | -116.74% | 0.22x | 1.73x | $-32.34 Million |
| 1997 | -89.11% | -95.11% | 0.28x | 3.38x | $-34.59 Million |
| 1998 | 0.00% | -109.69% | 0.41x | 0.00x | $-42.58 Million |
| 1999 | -7400.00% | -174.63% | 0.33x | 128.88x | $-59.28 Million |
| 2000 | -80.59% | -143.56% | 0.20x | 2.76x | $-60.12 Million |
| 2001 | -33.09% | -138.59% | 0.13x | 1.87x | $-96.14 Million |
| 2002 | -46.46% | -90.10% | 0.18x | 2.82x | $-87.79 Million |
| 2003 | -141.41% | -190.03% | 0.15x | 4.99x | $-101.71 Million |
| 2004 | 0.00% | -334.33% | 0.20x | 0.00x | $-135.29 Million |
| 2005 | -2716.74% | -180.40% | 0.24x | 62.43x | $-72.67 Million |
| 2006 | -66.95% | -308.92% | 0.06x | 3.73x | $-52.76 Million |
| 2007 | -1260.78% | -18.84% | 0.23x | 296.86x | $-11.08 Million |
| 2008 | -27.09% | -16.95% | 0.19x | 8.56x | $-24.88 Million |
| 2009 | 53.16% | 127.52% | 0.19x | 2.25x | $125.89 Million |
| 2010 | -25.05% | -56.47% | 0.20x | 2.25x | $-85.71 Million |
| 2011 | -49.47% | -85.58% | 0.20x | 2.83x | $-101.94 Million |
| 2012 | -35.83% | -64.16% | 0.19x | 2.99x | $-83.75 Million |
| 2013 | -16.03% | -41.17% | 0.17x | 2.24x | $-98.48 Million |
| 2014 | -15.12% | -18.20% | 0.22x | 3.71x | $-64.76 Million |
| 2015 | -43.97% | -31.12% | 0.30x | 4.76x | $-108.36 Million |
| 2016 | -86.93% | -24.97% | 0.38x | 9.16x | $-96.51 Million |
| 2017 | 0.10% | 0.07% | 0.39x | 4.00x | $-32.74 Million |
| 2018 | 26.12% | 45.65% | 0.22x | 2.55x | $168.93 Million |
| 2019 | 19.99% | 26.18% | 0.35x | 2.20x | $146.90 Million |
| 2020 | -57.77% | -66.80% | 0.31x | 2.84x | $-571.30 Million |
| 2021 | -3.70% | -3.53% | 0.31x | 3.38x | $-105.80 Million |
| 2022 | -47.08% | -45.92% | 0.23x | 4.42x | $-327.01 Million |
| 2023 | -94.72% | -46.50% | 0.26x | 7.73x | $-404.95 Million |
| 2024 | -77.15% | -64.37% | 0.23x | 5.11x | $-512.73 Million |
Industry Comparison
This section compares Ionis Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ionis Pharmaceuticals Inc (IONS) | $617.97 Million | -264.71% | 3.91x | $11.61 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |